| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
American Journal of Epidemiology Vol. 145, No. 4: 293-300
Copyright © 1997 by The Johns Hopkins University School of Hygiene and Public Health
research-article |
Progression of Human Immunodeficiency Virus Infection in Patients with Tuberculosis Disease
A Cohort Study in Bordeaux, France, 1988–1994
1UniversitÉ de Bordeaux II INSERM 330, France
2Centre Hospitalier Universitaire de Bordeaux France
Reprint requests to Dr. ValÉriane Leroy, UniversitÉ de Bordeaux II, UnitÉ INSERM 330, 146 rue LÉo Saignat, 33076 Bordeaux Cedex, France.
To assess the role of Mycobacterium tuberculosis disease in human immunodeficiency virus (HIV) infection, the authors compared survival of tuberculosis patients and controls matched on year of HIV diagnosis and CD4+ lymphocyte count. Patients were selected in the Aquitaine Cohort, which follows, since 1985, all patients infected with HIV, aged more than 13 years, in five hospitals. Time of inclusion of controls was the date of diagnosis of tuberculosis for the corresponding tuberculosis patient. Patients who had received primary prophylaxis against mycobacteria other than tuberculosis were excluded. As of June 30, 1994, 104 tuberculosis patients and 620 controls were selected; they were similar, except for history of intravenous drug use (tuberculosis patients, 51%, vs. controls, 31%) and AIDS-defining opportunistic infection (40 vs. 29%). Survival was shorter in tuberculosis patients than in controls (risk ratio 1.5, 95% confidence interval 1.2–2.1) even after controlling for differences at entry. The risk of AIDS-defining opportunistic infection or a decrease to fewer than 50 CD4+ cells/mm3 was slightly but not statistically greater in tuberculosis patients than in controls. Tuberculosis disease affected survival but not occurrence of subsequent opportunistic infections or rate of CD4+ count decline. Tuberculosis may be a marker of advanced HIV and may accelerate its course of infection. Am J Epidemiol 1997; 145: 293–300.
HIV infections; natural history; tuberculosis
3Groupe d'EpidÉmiologie Clinique du Sida en Aquitaine of the Centre Hospitalier Universrtaire de Bordeaux: Organizational and epidemiologic coordination—Profs. F. Dabis and R. Salamon, Dr. G. Chene; Medical coordination: Drs. J. Constans, M. Dupon, D. Lacoste, and P. Moriat; Profs. J-F. Moreau, J-L Pellegrin, and J-M. Ragnaud; Participating hospital departments: Bordeaux Hospital— Prof. J Aubertin (Prof. J-M. Ragnaud, Drs. M. Buisson and S. Sire), Prof. J. Beylot (Drs. N. Bernard, D. Lacoste, and P. Morlat), Prof. C.Beylot (Prof. M-S. Doutre), Prof. C. Conri (Dr. J. Constans), Profs. P. Couzigou and M. Geniaux (Mrs. A. Simon), Prof. J-Y. Lacut (Drs. M. Dupon and M-C. Paty), Prof. B. Leng (Prof. J-L Pellegrin, Drs. C. Desforges-Lasseur and P. Rispal), Prof. M. Le Bras (Drs. E. Monlun and J-P. Pivetaud), Prof. F. Moreau (Dr. C. Mestre), Prof. J. Paccalin (Dr. H. Dabadie), Profs. C. Series and A. Taytard (Dr. J-M. Vemejoux); Dax Hospital—Dr. P. Loste (Dr. I. Blanchard); Bayonne Hospital—Drs. M. Ferrand and F. Bonnal (Drs. Y. Blanchard and S. Farbos); Liboume Hospital—Drs. N. Carde and J. Ceccaldi (Dr. X. Jacquelin); Villeneuve-sur-Lot Hospital—Dr. G. Brossard; Data management and analysis: Mrs. J. Caie, M. Decoin, L. Dequae, M. Errecart-Banbotin, D. Touchard, D. Belougne, and Drs. D. Commenges, J-B. Hubert, C. Marimoutou, and V. Leroy.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H Lopez-Gatell, S. Cole, N. Hessol, A. French, R. Greenblatt, S Landesman, S Preston-Martin, and K Anastos Effect of Tuberculosis on the Survival of Women Infected with Human Immunodeficiency Virus Am. J. Epidemiol., May 15, 2007; 165(10): 1134 - 1142. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. A. Stringer, I. Zulu, J. Levy, E. M. Stringer, A. Mwango, B. H. Chi, V. Mtonga, S. Reid, R. A. Cantrell, M. Bulterys, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA, August 16, 2006; 296(7): 782 - 793. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. C. JONES-LOPEZ, A. OKWERA, H. MAYANJA-KIZZA, J. J. ELLNER, R. D. MUGERWA, C. C. WHALEN, and THE UGANDA-CASE WESTERN RESERVE UNIVERSITY RESEARC DELAYED-TYPE HYPERSENSITIVITY SKIN TEST REACTIVITY AND SURVIVAL IN HIV-INFECTED PATIENTS IN UGANDA: SHOULD ANERGY BE A CRITERION TO START ANTIRETROVIRAL THERAPY IN LOW-INCOME COUNTRIES? Am J Trop Med Hyg, January 1, 2006; 74(1): 154 - 161. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Lawn, S. T. Butera, and T. M. Folks Contribution of Immune Activation to the Pathogenesis and Transmission of Human Immunodeficiency Virus Type 1 Infection Clin. Microbiol. Rev., October 1, 2001; 14(4): 753 - 777. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. FitzGerald and S. Houston Tuberculosis: 8. The disease in association with HIV infection Can. Med. Assoc. J., July 1, 1999; 161(1): 47 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. C. SNYDER, E. A. PAZ, J. C. MOHLE-BOETANI, R. FALLSTAD, R. L. BLACK, and D. P. CHIN Tuberculosis Prevention in Methadone Maintenance Clinics . Effectiveness and Cost-Effectiveness Am. J. Respir. Crit. Care Med., July 1, 1999; 160(1): 178 - 185. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. Sawert, E. Girardi, G. Antonucci, M. C. Raviglione, P. Viale, G. Ippolito, and for the Gruppo Italiano di Studio Tubercolosi e AI Preventive Therapy for Tuberculosis in HIV-Infected Persons: Analysis of Policy Options Based on Tuberculin Status and CD4+Cell Count Arch Intern Med, October 26, 1998; 158(19): 2112 - 2121. [Abstract] [Full Text] [PDF]
|
|